2,2,2-trichloroethyl pyridin-3-ylcarbamate | 163239-03-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,2,2-trichloroethyl pyridin-3-ylcarbamate
• 英文别名: pyridine-3-ylcarbamic acid 2,2,2-trichloroethyl ester；2,2,2-trichloroethyl N-pyridin-3-ylcarbamate
• CAS: 163239-03-0
• 化学式: C₈H₇Cl₃N₂O₂
• 分子量: 269.515
• InChiKey: UVXBFRZZIQVXNU-UHFFFAOYSA-N

物化性质

• 沸点：
  303.9±42.0 °C(Predicted)
• 密度：
  1.559±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2,2-trichloroethyl pyridin-3-ylcarbamate 、 1-(4-联苯基)-哌嗪 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 16.0h， 以54.2%的产率得到4-biphenyl-4-yl-N-pyridine-3-ylpiperazine-1-carboxamide
  参考文献：
  名称：

  WO2007/20888

  摘要：

  公开号：
• 作为产物：
  描述：

  3-氨基吡啶 、 氯甲酸-2,2,2-三氯乙酯 在 吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以64%的产率得到2,2,2-trichloroethyl pyridin-3-ylcarbamate
  参考文献：
  名称：

  一系列哌嗪脲作为脂肪酸酰胺水解酶（FAAH）抑制剂的合成，SAR研究和生物学评估

  摘要：

  设计，合成和评价了一系列哌嗪尿素作为新型口服可用的脂肪酸酰胺水解酶（FAAH）抑制剂的潜力，这些抑制剂可有效治疗疼痛。我们对前导化合物3进行了优化研究，以改善其DMPK谱以及体外效价。我们鉴定出噻唑化合物60j具有强抑制活性，高脑通透性和良好的生物利用度。化合物60j在小鼠的乙酸诱导的扭体试验中显示出强效且剂量依赖性的抗伤害感受作用。

  DOI：

  10.1016/j.bmc.2012.11.006

文献信息

• AMIDE COMPOUND
  申请人：KORI Masakuni

  公开号：US20090163508A1

  公开（公告）日：2009-06-25

  An object of the present invention is to provide a novel fused-ring compound which has a FAAH inhibitory effect and is useful as an analgesic. The present invention relates to a compound represented by formula (I): wherein symbols are as defined in the specification, or salt thereof.

  本发明的一个目的是提供一种具有FAAH抑制作用并且作为镇痛药物有用的新型融环化合物。本发明涉及一种由下式表示的化合物： 其中符号如规范中定义的，或其盐。
• Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
  申请人：Matsumoto Takahiro

  公开号：US20090048263A1

  公开（公告）日：2009-02-19

  A compound represented by the formula (I) or a salt thereof; and an agent for protecting a brain/neuronal cell or a therapeutic agent for sleep disorder comprising the compound or salt: wherein Z represents an oxygen or sulfur; R 1 represents an aryl or heterocyclic group which may be substituted, provided that R 1 is not a 3-ethyl-6-methoxy-2-methyl-5-naphthalen-1-yl group; R 1a represents a hydrogen atom, a hydrocarbon group which may be substituted, a hydroxyl group or the like; R 2 represents a piperidin-1,4-diyl or piperazin-1,4-diyl which may be substituted; R 3 represents a bivalent group which is formed by removing two hydrogen atoms from a benzene ring or 6-membered aromatic heterocyclic ring which may have a substituent, provided that R 3 is not a pyridazin-3,6-diyl; and R 4 represents a group which is formed by removing one hydrogen atom from a benzene ring or 5- to 6-membered heterocyclic ring which may be substituted, provided that the substituent on the heterocyclic ring is not a phenylethyl group which may be substituted when Z is sulfur.

  化合物（I）的化学式或其盐；以及包含该化合物或盐的保护脑部/神经细胞的药剂或治疗失眠症的药剂：其中Z代表氧或硫；R1代表取代的芳基或杂环基，但R1不是3-乙基-6-甲氧基-2-甲基-5-萘基-1-基基；R1a代表氢原子，可取代的烃基，羟基或类似物；R2代表可取代的哌啶-1,4-二基或哌嗪-1,4-二基；R3代表双价基团，由苯环或6元芳杂环环上去掉两个氢原子形成，可以有取代基，但R3不是吡嗪-3,6-二基；R4代表由苯环或5-到6-元杂环环上去掉一个氢原子形成的基团，可以取代，但当Z是硫时，杂环环上的取代基不是可取代的苯乙基基团。
• Kinase inhibitors useful for the treatment of proliferative diseases
  申请人：Flynn L. Daniel

  公开号：US20080114006A1

  公开（公告）日：2008-05-15

  The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

  本发明涉及一种新型激酶抑制剂和调节剂化合物，用于治疗各种疾病。更具体地说，本发明涉及这样的化合物、激酶/化合物加合物、治疗疾病的方法以及合成化合物的方法。优选地，这些化合物对Raf激酶及其疾病多态性的激酶活性调节是有用的。本发明的化合物在哺乳动物癌症，特别是人类癌症，包括但不限于恶性黑色素瘤、结肠直肠癌、卵巢癌、乳头状甲状腺癌、非小细胞肺癌和间皮瘤的治疗中发挥作用。本发明的化合物也在治疗类风湿性关节炎和视网膜病变，包括糖尿病性视网膜神经病变和黄斑变性方面发挥作用。
• Amide Compound
  申请人：Matsumoto Takahiro

  公开号：US20080312226A1

  公开（公告）日：2008-12-18

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I 0 ): R 1 —C—R 2 —R 3 —R 4 (I 0 ) wherein Z is oxygen or sulfur; R 1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R 1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R 2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R 3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, —CO—, etc.; and R 4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  提供了一种FAAH抑制剂和预防或治疗脑血管疾病或睡眠障碍的药物，其中预防或治疗剂包括化合物(I0)的一种：R1-C-R2-R3-R4(I0)，其中Z为氧或硫；R1为芳基，可以被取代，或者是可以被取代的杂环基；R1a为氢原子，可以被取代的碳氢基，羟基等；R2为可以被取代的哌啶-1,4-二基，或者可以被取代的哌嗪-1,4-二基；R3为从具有1到3个氮、氧和硫杂原子的5元芳香杂环基中消除两个氢原子形成的基团，可以进一步被取代，-CO-等；R4为可以被取代的碳氢基或者可以被取代的杂环基；或其盐。
• Amide compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07851473B2

  公开（公告）日：2010-12-14

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I0): wherein Z is oxygen or sulfur; R1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, —CO—, etc.; and R4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  提供了一种FAAH抑制剂和用于预防或治疗脑血管疾病或睡眠障碍的预防性或治疗性制剂，它包括公式（I0）的化合物：其中Z是氧或硫；R1是取代的芳基或取代的杂环基；R1a是氢原子、可取代的碳氢基、羟基等；R2是可取代的哌啶-1,4-二基或可取代的哌嗪-1,4-二基；R3是由1至3个从氮、氧和硫中选择的杂原子构成的5-成员芳香杂环基消去两个氢原子形成的基团，它可以进一步取代，-CO-等；R4是可取代的碳氢基或可取代的杂环基；或其盐。